Testing of Coding Algorithms for Inflammatory Bowel Disease Identification, as Indication for Use of Biological Drugs, Using a Claims Database from Southern Italy

Background Inflammatory bowel diseases (IBDs), Crohn’s disease (CD) and ulcerative colitis (UC), are chronic diseases that have been increasingly treated with biological drugs in recent years. Newly developed coding algorithms for IBD identification using claims databases are needed to improve post-marketing surveillance of biological drugs. Objective To test algorithms to identify CD and UC, as indication for use of biological drugs approved for IBD treatment, using a claims database. Methods Data were extracted from the Caserta Local Health Unit database between 2015 and 2018. CD/UC diagnoses reported by specialists in electronic therapeutic plans (ETPs) were considered as gold standard. Five algorithms were developed based on ICD-9-CM codes as primary cause of hospital admissions, exemption from healthcare service co-payment codes and drugs dispensing with only indication for CD/UC. The accuracy was assessed by sensitivity (Se), specificity (Sp), positive (PPV) and negative predicted values (NPV) along with computation of the Youden Index and F-score. Results In the study period, 1205 subjects received at least one biological drug dispensing approved for IBD and 134 (11.1%) received ≥1 ETP with IBD as use indication. Patients with CD and CU were 83 (61.9%) and 51 (38.1%), respectively. Sensitivity of the different algorithms ranged from 71.1% (95% CI: 60.1–80.5) to 98.8 (95% CI: 93.5–100.0) for CD and from 64.7% (95% CI: 50.1–77.6) to 94.1 (95% CI: 83.8–98.8) for UC, while specificity was always higher than 91%. The best CD algorithm was “Algorithm 3”, based on hospital CD diagnosis code OR CD exemption code OR [IBD exemption code AND dispensing of non-biological drugs with only CD indication] (Se: 98.8%; Sp: 97.2%; PPV: 84.5%, NPV: 99.8%), achieving the highest diagnostic accuracy (Youden Index=0.960). The best UC algorithm was “Algorithm 3”, based on specific hospital UC diagnosis code OR UC exemption code OR [IBD exemption code AND golimumab dispensing] OR dispensing of non-biological drugs with only UC indication (Se: 94.1%; Sp: 91.6%; PPV: 50.0%; NPV: 99.4%), and achieving the highest diagnostic accuracy (Youden Index=0.857). Conclusion In a population-based claims database, newly coding algorithms including diagnostic and exemption codes plus specific drug dispensing yielded highly accurate identification of CD and UC as distinct indication for biological drug use.

[1]  M. Ragonese,et al.  Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases , 2022, Scientific Reports.

[2]  M. Massari,et al.  Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project , 2021, BioDrugs.

[3]  A. Cifu,et al.  Ulcerative Colitis in Adults. , 2020, JAMA.

[4]  M. Kwak,et al.  Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database , 2020, Journal of gastroenterology and hepatology.

[5]  Seoyoung C. Kim,et al.  Validation of claims‐based algorithms for psoriatic arthritis , 2019, Pharmacoepidemiology and drug safety.

[6]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[7]  T. H. Nguyen,et al.  The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[8]  G. Trifirò,et al.  In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study , 2019, BMC Nephrology.

[9]  G. Cappai,et al.  A Systematic Review of Case-Identification Algorithms for 18 Conditions Based on Italian Healthcare Administrative Databases: A Study Protocol. , 2019, Epidemiologia e prevenzione.

[10]  V. Gunaseelan,et al.  Databases for surgical health services research: Clinformatics Data Mart☆ , 2019, Surgery.

[11]  G. Kaplan,et al.  Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. , 2019, Gastroenterology.

[12]  Ashwin N. Ananthakrishnan,et al.  ACG Clinical Guideline: Ulcerative Colitis in Adults , 2019, The American journal of gastroenterology.

[13]  K. Huybrechts,et al.  Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries , 2019, European Journal of Clinical Pharmacology.

[14]  D. Bennett,et al.  Identifying Patients With Inflammatory Bowel Diseases in an Administrative Health Claims Database: Do Algorithms Generate Similar Findings? , 2019, Inquiry : a journal of medical care organization, provision and financing.

[15]  L. Naldi,et al.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? , 2018, Drug Safety.

[16]  S. Rhee,et al.  Trends in health‐care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population‐based study , 2018, Journal of gastroenterology and hepatology.

[17]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[18]  C. la Vecchia,et al.  Crohn's disease in Italy: A critical review of the literature using different data sources. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[19]  G. Trifirò,et al.  How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 , 2016, BioDrugs.

[20]  Matthias Eikermann,et al.  Codifying healthcare – big data and the issue of misclassification , 2015, BMC Anesthesiology.

[21]  G. Trifirò,et al.  How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 , 2015, BioDrugs.

[22]  E. Clementi,et al.  Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study , 2014, ClinicoEconomics and outcomes research : CEOR.

[23]  G. Cappai,et al.  Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[24]  A. Forster,et al.  Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. , 2014, Journal of clinical epidemiology.

[25]  G. Trifirò,et al.  The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy , 2014, PloS one.

[26]  N. Pedersen,et al.  East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort , 2013, Gut.

[27]  H. Quan,et al.  Development and validation of an administrative case definition for inflammatory bowel diseases. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[28]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[29]  L. Lakatos,et al.  Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006 , 2011, Inflammatory bowel diseases.

[30]  Gabriella Guasticchi,et al.  Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources , 2011, BMC public health.

[31]  Philippe Seksik,et al.  Epidemiology and natural history of inflammatory bowel diseases. , 2011, Gastroenterology.

[32]  N. Abraham,et al.  Validation of ICD-9-CM Diagnostic Codes for Inflammatory Bowel Disease Among Veterans , 2010, Digestive Diseases and Sciences.

[33]  C. Romano,et al.  Indeterminate Colitis: A Distinctive Clinical Pattern of Inflammatory Bowel Disease in Children , 2008, Pediatrics.

[34]  Ken Kleinman,et al.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  W. Bilker,et al.  Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease , 2002, Pharmacoepidemiology and drug safety.

[36]  阎明,et al.  Epidemiology and Natural History of Inflammatory Bowel Disease , 2001 .

[37]  A Wajda,et al.  Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. , 1999, American journal of epidemiology.

[38]  H. Sørensen,et al.  Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. , 1996, Scandinavian journal of gastroenterology.

[39]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.